Kainos Medicine KRX:284620KOSDAQ

카이노스메드 · Korean news coverage and regulatory filings, organized.

Articles, 24h0
Articles, 7 days0
DART filings, 7 days1
Articles tracked3since Sep 11

In Q3 2026, Kainos Medicine reported revenue of ₩402m, up 24.8% year on year, and an operating loss of ₩582m. Kainos Medicine (카이노스메드) appeared in 0 Korean news articles and 1 DART filing over the past seven days.

Filing signals 4 quarters of losses Screener

Kainos Medicine today: up or down?

No sign-up, one tap a day. These numbers show what visitors think and are not investment advice.

Upcoming dates as filed

  • Mar 31 Annual report filing deadlinein 134 days · period ending Dec 2026

Dates Kainos Medicine stated in its DART filings. A conversion period opening does not mean new shares appear that day; bondholders must request conversion.

Kainos Medicine quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q3 2026₩402m+24.8%−₩582m
margin −144.8%
−₩928m
Q2 2026₩408m+131.2%−₩1.1bn
margin −258.1%
−₩1.3bn
Q1 2026₩370m+0.4%−₩1.0bn
margin −273.2%
−₩1.3bn
Q4 2025 derived₩304m+326.3%−₩2.3bn−₩1.9bn
Q3 2025₩322m+58.2%−₩1.5bn−₩1.8bn
Q2 2025₩176m-0.1%−₩945m−₩1.9bn
Q1 2025₩369m+165.9%−₩1.7bn−₩2.2bn
Q4 2024 derived₩71m-29.4%−₩4.2bn−₩4.2bn

Kainos Medicine ranks #1659 of 2,345 Korean listed companies by Q3 2026 operating profit. Q3 2026 Korean earnings rankings →

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Kainos Medicine top stories 2 weeks, by number of outlets

No story covered by multiple outlets in the past two weeks.

Latest Kainos Medicine news Korean headlines